Summary by Futu AI
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased a total of 5,279,036 A-shares through the Shanghai Stock Exchange between March 8 and April 2, 2024. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. The share repurchase operation began on March 11, 2024, repurchased 937,079 shares on the same day and ended on April 2, with the repurchase of 426,774 shares on the same day. The repurchase price is between RMB 46.54 and RMB 57.32, and the total number of shares repurchased represents a percentage of the Company's shares issued prior to the repurchase not exceeding 0.02%. The Company confirms that all repurchases have been approved by the Board of Directors and comply with the relevant legal requirements. After the share repurchase, the company had a deposit of 2,546,260,847 shares on April 2, 2024.